Jul 1 |
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
|
Jun 8 |
GSK, SpringWorks end collaboration agreement
|
Jun 6 |
Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
|
Jun 6 |
Insider Sale: COO Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX)
|
Jun 6 |
Insider Sale: CEO Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc (SWTX)
|
Jun 5 |
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
May 23 |
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
May 8 |
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
|
May 5 |
SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript
|
May 5 |
SpringWorks Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
|